Partnerships: NIA/NIH/FDA collaboration

Enable close collaboration between NIH and FDA to advance biomarkers and therapy development for AD/ADRD.

2030 14.O In Progress Collaboration to advance biomarkers and therapy development for AD/ADRD DN 2021 AD Summit: 5.M Public Private Partnerships NIA/FDA Memorandum of Understanding (MoU) 2024

  • Convene joint workshops, public symposia, and establish MOUs to promote a close collaboration between NIH and FDA for the advancement of biomarker and therapy development for AD/ADRD.

Summary of Key Accomplishments

In 2024, NIA and the Food and Drug Administration (FDA) established a Memorandum of Understanding to strengthen the NIA/FDA collaborations to accelerate the development of medical products (e.g., drugs, diagnostics, drug development tools) to treat and prevent AD/ADRD.

The key accomplishments summary is current as of September 2025.